Alan has a degree in Finance from Birmingham University and is a chartered accountant. He is a founding partner of Bridgepoint Development Capital (BDC), where he sits on the Board and its Operating Committee, and is a member of its Investment Advisory Committee. Alan joined BDC in 1996 and is currently a board member for portfolio companies Monica Vinader and Analysys Mason. He has led a broad range of transactions, including public-to-private and serial international buy-and-build investments; previous transactions have included working with HKA, Matrix, Quotient Clinical, Phlexglobal, LOC Group, BigHand, The Energy Solutions Group, Pulsant and Safestore PLC. Prior to joining BDC, he worked for Deloitte (formerly Arthur Andersen) on its corporate finance team.
Featured
Prescient Intelligence
Discover our portfolio of AI-powered assessments and intelligent tools designed to support better strategic decisions.
News and insights
Featured
Strategy that learns: Rethinking brand planning for a changing environment
Explore why the strongest brand strategies continue beyond annual planning.
Discover The Prescient Pharma Brand Plan Impact Index
Helping senior leaders strengthen strategy and drive better business performance.
The Four Positioning Challenges Every Pharma Launch Team Must Overcome
Discover four positioning challenges that every pharma launch team should address.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
